RVMD — Revolution Medicines Share Price
Last trade - 00:00- $40.57bn
- $37.66bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.56 | ||
| Price to Tang. Book | 16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41% | ||
| Return on Equity | -79.09% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 29.39 | 35.38 | 11.58 | n/a | n/a | 173.06 | 1,166.85 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.
Directors
- Mark Goldsmith CHM (59)
- Steve Kelsey CEX (58)
- Margaret Horn COO (58)
- Xiaolin Wang EVP (51)
- Alexis Borisy LED (49)
- Elizabeth Anderson IND (63)
- Neil Exter IND (62)
- Vincent Miller IND (59)
- Eric Schmidt IND (52)
- Thilo Schroeder IND (39)
- Barbara Weber IND (64)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 7th, 2014
- Public Since
- February 13th, 2020
- No. of Shareholders
- 46
- No. of Employees
- 883
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 214,336,418
- Address
- 700 Saginaw Dr, REDWOOD CITY, 94063
- Web
- https://www.revmed.com/
- Phone
- +1 6504816801
- Auditors
- PricewaterhouseCoopers LLP
Latest News for RVMD
Upcoming Events for RVMD
Q3 2026 Revolution Medicines Inc Earnings Release
Q4 2026 Revolution Medicines Inc Earnings Release
Similar to RVMD
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 04:59 UTC, shares in Revolution Medicines are trading at $189.26. This share price information is delayed by 15 minutes.
Shares in Revolution Medicines last closed at $189.26 and the price had moved by +281.88% over the past 365 days. In terms of relative price strength the Revolution Medicines share price has outperformed the S&P500 Index by +226.9% over the past year.
The overall consensus recommendation for Revolution Medicines is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRevolution Medicines does not currently pay a dividend.
Revolution Medicines does not currently pay a dividend.
Revolution Medicines does not currently pay a dividend.
To buy shares in Revolution Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $189.26, shares in Revolution Medicines had a market capitalisation of $40.57bn.
Here are the trading details for Revolution Medicines:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RVMD
Based on an overall assessment of its quality, value and momentum Revolution Medicines is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Revolution Medicines is $259.78. That is 37.26% above the last closing price of $189.26.
Analysts covering Revolution Medicines currently have a consensus Earnings Per Share (EPS) forecast of -$9.60 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Revolution Medicines. Over the past six months, its share price has outperformed the S&P500 Index by +16.9%.
As of the last closing price of $189.26, shares in Revolution Medicines were trading +25.23% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Revolution Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $189.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Revolution Medicines' management team is headed by:
- Mark Goldsmith - CHM
- Steve Kelsey - CEX
- Margaret Horn - COO
- Xiaolin Wang - EVP
- Alexis Borisy - LED
- Elizabeth Anderson - IND
- Neil Exter - IND
- Vincent Miller - IND
- Eric Schmidt - IND
- Thilo Schroeder - IND
- Barbara Weber - IND